MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Open Access
- 1 November 2012
- journal article
- research article
- Published by Elsevier BV in Cell
- Vol. 151 (5), 937-950
- https://doi.org/10.1016/j.cell.2012.10.035
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease OutcomeCell, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma OutcomeCancer Cell, 2009
- Non-Smad pathways in TGF-β signalingCell Research, 2008
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activityNature, 2008
- Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescenceNature, 2006